Top

Published in:

Open Access 01-12-2016 | Case report

Recombinant growth hormone therapy in a girl with costello syndrome: a 4-year observation

Authors: Ewa Blachowska, Elżbieta Petriczko, Anita Horodnicka-Józwa, Agata Skórka, Magdalena Pelc, Małgorzata Krajewska-Walasek, Mieczysław Walczak

Published in: Italian Journal of Pediatrics | Issue 1/2016

Abstract

Background

Costello syndrome is a rare syndrome of multiple congenital anomalies. The typical clinical traits include dysmorphic craniofacial features, skin hyperpigmentation and excess, feeding difficulties leading to severe postnatal growth retardation, short stature, joint hypermobility, and delayed psychomotor development. Additionally, Costello syndrome may present with an increased incidence of congenital heart disease, hypertrophic cardiomyopathy, and increased risk of both benign and malignant tumors. Furthermore, cases of patients with endocrine disorders such as adrenal insufficiency and endogenous growth hormone deficiency have also been documented.

Case presentation

We present a patient with Costello syndrome who has been successfully treated with recombinant human growth hormone (rhGH) for almost 4 years.

Conclusions

The possibility of growth hormone (GH) treatment can be considered in cases of documented GH deficiency in patients with Costello syndrome, but only under close oncologic and cardiologic supervision.

Gripp KW, Lin AE. Costello Syndrome. GeneReviews^® University of Washington, Initial Posting: August 29, 2006; Last Update: January 12, 2012.

Aoki Y, Niihori T, Kawame H, Kurosawa K, Ohashi H, Tanaka Y, et al. Germline mutations in HRAS proto-oncogen cause Costello syndrome. Nat Genet. 2005;37:1038–40.CrossRefPubMed

Kerr B, Delrue M-A, Sigaudy S, Perveen R, Marche M, Burgelin I, et al. Genotype-phenotype correlation in Costello syndrome: HRAS mutation analysis in 43 cases. J Med Genet. 2006;43:401–5. doi:10.1136/jmg.2005.040352.PubMedCentralCrossRefPubMed

Pelc M, Ciara E, Krajewska-Walasek M. Zespół Costello jako przykład rzadkich zaburzeń funkcji szlaku sygnalnego Ras-MAPK: obraz kliniczny i diagnostyka molekularna choroby. Pediatr Pol. 2012;87:19–32.CrossRef

Gripp KW, Scott CI, Nicholson L, McDonald-McGinn DM, Ozeran JD, Jones MC, et al. Five additional Costello syndrome patients with rhabdomyosarcoma: proposal for a tumor screening protocol. Am J Med Genet. 2002;108:80–7.CrossRefPubMed

Kerr B, Eden B, Dandamudi R, Shannon N, Quarrell O, Emmerson A, et al. Costello syndrome: two cases with embryonal rhabdomyosarcoma. J Med Genet. 1998;35:1036–9.PubMedCentralCrossRefPubMed

van Eeghen AM, van Gelderen I, Hennekam RCM. Costello syndrome: report and review. Am J Med Genet. 1999;82:187–93.CrossRefPubMed

Gregersen N, Viljoen D. Costello syndrome with growth hormone deficiency and hypoglycemia: a new report and review of the endocrine associations. Am J Med Genet Part A. 2004;129A:171–5.CrossRefPubMed

Okamoto N, Chiyo H, Imai K, Otani K, Futagi Y. A Japanese patient with the Costello syndrome. Hum Genet. 1994;93:605–6.CrossRefPubMed

10.

Schimke RN, Donaldson D, Moore W. Growth hormone deficiency in Costello syndrome. Proc Greenwood Genet Ctr. 1996;15:195.

11.

Yetkin I, Ayvaz G, Arslan M, Yilmaz M, Cakir N. A case of Costello syndrome with endocrine features. Ann Genet. 1998;41:157–60.PubMed

12.

Legault L, Gagnon C, Lapointe N. Growth hormone deficiency in Costello syndrome: a possible explanation for the short stature. J Pediatr. 2001;138:151–2.CrossRefPubMed

13.

Stein RI, Legault L, Daneman D, Weksberg R, Hamilton J. Growth Hormone Deficiency in Costello Syndrome. Am J Med Genet Part A. 2004;129A:166–70.CrossRefPubMed

14.

Kerr B, Einaudi MA, Clayton P, Gladman G, Eden T, Saunier P, et al. Is growth hormone treatment beneficial or harmful in Costello syndrome? J Med Genet. 2003;40, e74.PubMedCentralCrossRefPubMed

15.

Rauen KA, Hefner E, Carrillo K, Taylor J, Messier L, Aoki Y, et al. Molecular Aspects, Clinical Aspects and Possible Treatment Modalities for Costello Syndrome: Proceedings From the 1st International Costello Syndrome Research Symposium 2007. Am J Med Genet Part A. 2008;146A:1205–17.CrossRefPubMed

16.

Gripp KW, Scott CI, Nicholson L, Figueroa TE. Second case of bladder carcinoma in a patient with Costello syndrome. Am J Med Genet. 2000;90:256–9.CrossRefPubMed

17.

Kobayashi D, Cook AL, Williams DA. Progressively worsening hypertrophic cardiomyopathy in a child with newly diagnosed Costello syndrome while receiving growth hormone therapy. Cardiol Young. 2010;20:459–61. doi:10.1017/S1047951110000260.EpubMar22.CrossRefPubMed

Title: Recombinant growth hormone therapy in a girl with costello syndrome: a 4-year observation
Authors: Ewa Blachowska
Elżbieta Petriczko
Anita Horodnicka-Józwa
Agata Skórka
Magdalena Pelc
Małgorzata Krajewska-Walasek
Mieczysław Walczak
Publication date: 01-12-2016
Publisher: BioMed Central
Published in: Italian Journal of Pediatrics / Issue 1/2016
Electronic ISSN: 1824-7288
DOI: https://doi.org/10.1186/s13052-015-0209-4

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Recombinant growth hormone therapy in a girl with costello syndrome: a 4-year observation

Abstract

Background

Case presentation

Conclusions

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Case presentation

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2016

Gestational weight gain and fetal growth in underweight women

Sleep-wake cycle on amplitude-integrated EEG and neuroimage outcomes in newborns

Performances of low level hospital health caregivers after a neonatal resuscitation course

New program for identification of child maltreatment in emergency department: preliminary data

Neonatal diffusion tensor brain imaging predicts later motor outcome in preterm neonates with white matter abnormalities

Effects of Holder pasteurization on the protein profile of human milk